SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

BACKGROUND: Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons in Qatar. METHODS: All SARS-CoV-2 antibody-positive persons from April 16...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:EClinicalMedicine
Päätekijät: Abu-Raddad, Laith J., Chemaitelly, Hiam, Coyle, Peter, Malek, Joel A., Ahmed, Ayeda A., Mohamoud, Yasmin A., Younuskunju, Shameem, Ayoub, Houssein H., Al Kanaani, Zaina, Al Kuwari, Einas, Butt, Adeel A., Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F., Nasrallah, Gheyath K., Yassine, Hadi M., Al Kuwari, Mohamed Ghaith, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H., Al Khal, Abdullatif, Bertollini, Roberto
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2021
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8079668/
https://ncbi.nlm.nih.gov/pubmed/33937733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100861
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia